Message #77 From:
NewsBot Date: December 12, 2006 07:09:00 AM
NYMX News Nymox NXC-4720 Reduces E. Coli Contamination By 99%
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is developing is
developing NXC-4720, the Company’s innovative
new product targeting E. coli O157:H7 food poisoning at its
source: the contamination of food products. Studies have shown that
NXC-4720 is capable of reducing the level of E. coli O157:H7
contamination by over 99%.
Recent outbreaks of E. coli O157:H7 food poisoning highlight the
vulnerability of the U.S. food supply chain and food industry to this
serious public health hazard. As of December 10, 2006, 61 persons in
northeastern U.S. had reported sick as a result of E. coli
O157:H7 food poisoning with 50 requiring hospitalization. Preliminary
results point to contamination of green onions. An earlier outbreak of E.
coli O157:H7 contamination of fresh spinach in September 2006 left
three people dead and over 100 people hospitalized. Children and the
elderly are particularly at risk for the effects of this serious illness.
Nymox has patent rights covering novel treatments for E. coli
contamination and infection as well as other anti-bacterial treatments,
including three issued U.S. patents, other international versions of
these patents, as well as numerous pending patent applications both in
the U.S. and abroad.
Despite efforts to improve the safety of the food supply system,
outbreaks of potentially deadly E. coli O157 food contamination
remain common, both in the U.S. and around the world, including England,
Ireland, France, and Canada. The Centers for Disease Control (CDC)
estimates that E. coli O157 infections cause 73,000 illnesses
annually in the U.S. alone, resulting in more than 2,000
hospitalizations and 60 deaths. A recent study by the U.S. Department of
Agriculture estimated that the annual cost of illness due to E. coli
O157 was $404 million, including $370 million for premature deaths:
Frenzen PD et al, Journal of Food Protection 2005; 68:2623-2630.
This press release contains certain “forward-looking
statements” as defined in the United States
Private Securities Litigation Reform Act of 1995 that involve a number
of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future
events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.
